NEW YORK (GenomeWeb) – Indi Molecular said today that it has entered into a co-development deal with Sigma-Aldrich to explore the use of Indi Molecular's PCC (protein catalyzed capture) agent technology in Sigma-Aldrich's line of biological reagents.

The project will analyze using the PCC agents, which are synthetic peptides capable of protein binding with similar performance to traditional antibodies and with potentially lower development times and costs, for protein research.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A former Synthetic Genomics attorney alleges that the firm discriminated against her and other female employees, according to the San Diego Union-Tribune.

Due to privacy and lab certification questions, the planned giveaway of Orig3n testing kits at a Baltimore Ravens game was suspended.

Alnylam reports positive results from its phase 3 clinical trial of an RNAi-based drug, according to Stat News.

In Cell this week: adult mesenchymal cell populations in mouse lung, genetic diversity in HPV16 and cancer risk protection, and more.

Oct
10
Sponsored by
PerkinElmer

This online, interactive seminar will answer researchers’ most pressing questions about how to gain outstanding research results from proteomic studies.